Publications -

1. Ibrahim M, Abdul-Kader M, Azizi A, Schneider E, Salyer G, Ivory J, Reece-Orr N, O’Donnell H, Gerace L, Foster Z, Mariño del Puerto A, Chen Y, and Adams BD†. The miRNA-9 Isoform Story in Cancer: An OncomiR or Tumor Suppressor? Journal of Cancer Biomoleculars and Therapeutics. 2025; 2(2):. DOI:  10.62382/jcbt.v2i2.53 [Epub ahead of print]
2. Luu C, Salyer G, Gerace L, Abdul-Kader M, Azizi A, Puerto AM, and Adams BD†. Tumor Suppressor microRNAs as Potential Treatment Therapeutics for Advanced Medulloblastoma. Journal of Cancer Biomoleculars and Therapeutics. 2025; 2(1):45-56. DOI: 10.62382/jcbt.v2i1.31. [Epub ahead of print]
3. Ihsan M, Khan NU, Asim N, Ismail M, Almutairi MH, Ali I, and Adams BD†. Significant Association of Candidate Genes (AGTR1 and TGF-Β1) Polymorphism with Diabetic Nephropathy in Diabetes Mellitus Type 2 Patients. Cell Physiol Biochem. 2024 May 6;58(3):203-211. DOI: 10.33594/000000702. [Epub ahead of print]
4. Batool M, Khan NU, Khan H, Almutairi MH, Ali I, and Adams BD†. BRAF and RET polymorphism association with thyroid cancer risk, a preliminary study from Khyber Pakhtunkhwa population. Mol Biol Rep. 2024 Apr 10;51(1):502. DOI: 10.1007/s11033-024-09480-y. [Epub ahead of print]
5. Chen Y, Mateski J, Gerace L, Wheeler J, Burl J, Prakash B, Svedin C, Amrick R, Adams BD†. Non-coding RNAs and neuroinflammation: implications for neurological disorders. Experimental Biology and Medicine. 2024. DOI: 10.1007/s11033-023-08463. [Epub ahead of print]
6. Khan Y, Khan NU, Ali I, Khan S, Khan AU, Iqbal A, Adams BD†. Significant association of BRCA1 (rs1799950), BRCA2 (rs144848) and TP53 (rs1042522) polymorphism with breast cancer risk in Pashtun population of Khyber Pakhtunkhwa, Pakistan. Molecular Biology Reports. 2022. DOI: 10.1007/s11033-023-08463. [Epub ahead of print]
7. Rupaimoole R, Yoon B, Zhang WC, Adams BD*, Slack FJ. A High-Throughput Small Molecule Screen Identifies Ouabain as Synergistic with miR-34a in Killing Lung Cancer Cells. iScience. 2020. DOI: 10.1016/j.isci.2020.100878. [Epub ahead of print]
8. Jiao AL, Perales R, Umbreit NT, Haswell JR, Piper ME, Adams BD*, Pellman D, Kennedy S, Slack FJ. Human nuclear RNAi-defective 2 is an essential RNA Splicing factor. RNA. 2019. DOI 10.1261/rna.069773.1184-4722.2018.11. [Epub ahead of print]
9. Parsons C, Tayoun AM, Benado BD, Ragusa G, Dorvil RF, Rourke EA, Connor KO, Reed IG, Alexander A, Willetts L, Habibian M, Adams BD†. The role of long noncoding RNAs in cancer metastasis. J Cancer Metastasis Treat. 2018. DOI: 10.20517/2394-4722.2018.11. [Epub ahead of print].
10. Adams BD†, Arem H, Hubal, MJ, Cartmel B, et al. Exercise and weight loss interventions and miRNA expression in women with breast cancer. Breast Cancer Res Treat. 2018. DOI: 10.1007/s10549-018-4738-6. [Epub ahead of print].
11. Abdul-Rahman U, Győrffy B, and Adams BD†. (ERRLR01) is a Prognostic Indicator of Overall Survival in Breast Cancer. Transcription. 2017. [Epub ahead of print].
12. Roberts NA, Adams BD*, McCarthy NI, Tooze RM, Parnell SM, Anderson G, Kaech SM, and Horsley V. Prdm1 Regulates Thymic Epithelial Function to Prevent Autoimmunity. The Journal of Immunology. 2017; pii: ji1600941. DOI: 10.4049/jimmunol.1600941 [Epub ahead of print].
13. Chua FY and Adams BD†. Androgen Receptor and miR-206 Regulation in Prostate Cancer. Transcription. 2017.  DOI: 10.1080/21541264.2017.1322668  [Epub ahead of print].
14. Singh T and Adams BD†. The Regulatory Role of miRNAs on VDR in Breast Cancer. Transcription. 2017. DOI: 10.1080/21541264.2017.1317695  [Epub ahead of print].
15. Adams BD*,†, Parsons C, Walker L, Zhang WC, Slack FJ. Targeting Noncoding RNAs in Disease. J Clin Invest. 2017;127(3):761-771. DOI:10.1172/JCI84424
16. Metheetrairut C*, Adams BD*, Nallur S, Weidhaas J, and Slack FJ. cel-mir-237 and its Homologue, hsa-miR-125b, Modulate the Cellular Response to Ionizing Radiation. Oncogene
17. Gonzalez-Martin A, Adams BD*, Lai M, Shepherd J, Salvador-Bernaldez M, Salvador JM, Lu J, Nemazee D, and Xiao C. The microRNA miR-148a functions as a critical regulator of B cell tolerance and autoimmunity. Nat Immunol. 2015 [Epub ahead of print]. DOI: 10.1038/ni.3385
18. Adams BD*, Wali VB, Cheng CJ, Inukai S, Booth CJ, Agarwal S, Rimm DL, Győrffy B, Santarpia L, Pusztai L, Saltzman WM, and Slack FJ. miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple Negative Breast Cancer. Cancer Res 2015;(Epub ahead of print).  DOI: 1158/0008-5472.CAN-15-2321
19. Adams BD*, Parsons C*, and Slack FJ. The Tumor-Suppressive and Potential Therapeutic Functions of miR-34a in Epithelial Carcinomas. Expert Opin Ther Targets2015;(Epub ahead of print).  DOI: 10.1517/14728222.2016.1114102
20. Adams BD*, Anastasiadou E, Esteller M, He L, and Slack FJ. The Inescapable Influence of Noncoding RNAs in Cancer. Cancer Res2015;(Epub ahead of print).  DOI: 10.1158/0008-5472.CAN-15-1989
21. Adams BD*, and Slack FJ. MicroRNA Signatures as Biomarkers in Cancer. In: eLS. (June 2015) 1-20. John Wiley & Sons, Ltd: Chichester. DOI: 10.1002/9780470015902.a0025346
22. Adams BD*, Kasinski AL*, and Slack FJ. Aberrant Regulation and Function of MicroRNAs in Cancer. Curr Biol 2014; 24:R762-R776.  DOI: 10.1016/j.cub.2014.06.043
23. Bryniarski K, Ptak W, Jayakumar A, Püllmann K, Caplan MJ, Chairoungdua A, Lu J, Adams BD*, Sikora E, Nazimek K, Marquez S, Kleinstein SH, Sangwung P, Iwakiri Y, Delgato E, Redegeld F, Blokhuis BR, Wojcikowski J, Daniel AW, Groot Kormelink T, and Askenase PW. Antigen Specific Antibody Coated Exosome-Like Nanovesicles Deliver Suppressor T Cell microRNA-150 to Effector T Cells to Inhibit Contact Sensitivity. J Allergy Clin Immunol 2013; 132:170-181.  DOI: 10.1016/j.jaci.2013.04.048
24. Adams BD*, Guo S, Bai H, Guo Y, Megyola CM, Cheng J, Heydari K, Xiao C, Reddy EP, and Lu An In Vivo Functional Screen Uncovers miR-150-Mediated Regulation of Hematopoietic Injury Response. Cell Rep 2012; 2:1048-1060. DOI: 10.1016/j.celrep.2012.09.014
25. Hysolli E, Zhou XL, Liu R, Kim JH, Adams BD*, Sullivan G, Park IH. Role of pluripotent Stem Cells in Regenerative Medicine. In: Hay DC, (ed). Regenerative Medicine, Stem Cells and the Liver. Enfield: Science Publishers, 2012:21-37.
26. Guttilla IK,Adams BD*, and White BA. ERα, microRNAs, and the epithelial-mesenchymal transition in breast cancer. Trends Endocrinol Metab 2012; 23:73-82.  DOI: 10.1016/j.tem.2011.12.001
27. Adams BD*, Cowee DM, and White BA. The Role of miR-206 in The Epidermal Growth Factor (EGF) Induced Repression of Estrogen Receptor-alpha (ERα) Signaling and a Luminal Phenotype in MCF-7 Breast Cancer Cells. Mol Endocrinol 2009; 23:1215-1230.  DOI: 10.1210/me.2009-0062
28. Adams BD*, Claffey KP, and White BA. Argonaute-2 Expression is Regulated by EGFR/MAPK Signaling and Correlates with a Transformed Phenotype in Breast Cancer Cells. Endocrinology 2009; 150:14-23.  DOI: 10.1210/en.2008-0984
29. Adams BD*, Guttilla IK, and White BA. Involvement of MicroRNAs in Breast Cancer. Semin Reprod Med 2008; 26:522-536.  DOI: 10.1055/s-0028-1096132
30. Adams BD*, Furneaux H, and White BA. The micro-RNA miR-206 Targets the Human Estrogen Receptor-α, and Represses ERα mRNA and Protein Expression in Breast Cancer Cell Lines. Mol Endocrinol 2007; 21:1132-1147. DOI: 10.1210/me.2007-0022
31. Milstone LM, Adams BD*, Zhou J, Bruegel-Sanchez VL, and Shofner J. Stratum-specific Expression of Human Transferrin Receptor Increases Iron in Mouse Epidermis. J Invest Dermatol 2006; 126:648-652
32. Adams BD*, Lazova R, Andrews NC, and Milstone LM. Iron in Skin of Mice with Three Etiologies of Systemic Iron Overload. J Invest Dermatol 2005; 125:1200-1205.  DOI: 10.1111/j.0022-202X.2005.23949

 

• * These authors contributed equally
• † Corresponding author manuscript

 

https://www.ncbi.nlm.nih.gov/myncbi/browse/collection/51051850/?sort=date&direction=+descending